🟢 Nuvation Bio is trading 5% up today after second-quarter revenue beat expectations

Nuvation Bio is trading 4.99% up now at $6.41 after investors reassessed its August 6 earnings.

• Second-quarter revenue reached $31.7 million, beating expectations.
• IBTROZI product revenue rose 25% sequentially to $23.2 million.
• The advance follows an EPS miss: a $0.18 loss versus an expected $0.15 loss, suggesting investors are prioritizing commercial momentum and reaffirmed confidence in second-half revenue acceleration.